Content
Frontiers of Medicine >> 2023, Volume 17, Issue 2 doi: 10.1007/s11684-022-0939-9
Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial
Abstract
Keywords
neoadjuvant ; radiotherapy ; oligometastatic ; prostate cancer ; radical prostatectomy
Content